成都小腿静脉曲张手术多钱成都下肢静脉血栓价格,成都哪里雷诺氏综合症看的好,成都治疗脉管畸形医院哪家好,成都静脉曲张开刀哪家医院,成都好的医院治疗小腿血管炎,成都老烂腿哪个医院好,成都治疗肝血管瘤哪个医院

The first cruise in the Caribbean since the start of the pandemic is reporting a COVID-19 case.A passenger aboard SeaDream Yacht Club’s SeaDream 1 received a preliminary positive COVID-19 test.According to passengers, the captain informed them about the preliminary positive test over the ship’s intercom system while they were anchored off the coast of Grenadines.The vessel is now headed back to Barbados, where it is based.The SeaDream is carrying 53 passengers and 66 crew, with the majority of passengers hailing from the U.S. according to Sue Bryant, who is aboard the ship and is a cruise editor for The Times and The Sunday Times in Britain.The SeaDream is the first vessel to resume sailing in the Caribbean since earlier this year when coronavirus pandemic concerns docked the cruise industry following high profile infections.Passengers were tested both in advance of traveling, before boarding, and again a few days into the trip.The SeaDream has a capacity of about 110 guests and 95 crewmembers. It also sails outside of U.S. waters. This puts it below the 250 guests threshold and outside the area under the CDC’s orders about cruising. 1159

The decision to forego local bubbles was jointly recommended by NFL and NFLPA medical experts based on COVID testing data. They’re happy with the numbers and sticking with what works. Here’s the full memo, which also updates return to play protocols, etc. pic.twitter.com/GQxF0IF3jt— Tom Pelissero (@TomPelissero) December 15, 2020 345

The Food and Drug Administration on Wednesday authorized the first rapid coronavirus test that doesn’t need any special computer equipment to get results.The 15-minute test from Abbott Laboratories will sell for , giving it a competitive edge over similar tests that need to be popped into a small machine. The size of a credit card, the self-contained test is based on the same technology used to test for the flu, strep throat and other infections.It’s the latest cheaper, simpler test to hit the U.S. market, providing new options to expand testing as schools and businesses struggle to reopen and flu season approaches. The FDA also recently greenlighted a saliva test from Yale University that bypasses some of the supplies that have led to testing bottlenecks.Both tests have limitations and neither can be done at home. Several companies are developing rapid, at-home tests, but none have yet won approval. Abbott’s new test still requires a nasal swab by a health worker, like most older coronavirus tests. The Yale saliva test eliminates the need for a swab, but can only be run at high-grade laboratories.And in general, rapid tests like Abbott’s are less accurate than lab-developed tests. The FDA said in a statement announcing the decision that negative results with Abbott’s test may need to be confirmed with a lab test in some cases. The agency granted Abbott’s test an emergency use authorization late Wednesday for patients with suspected COVID-19.The two additions should help expand the number of available tests. The U.S. is now testing about 690,000 people per day, down from a peak of 850,000 daily tests late last month. Many public health experts believe the country will soon need to test vastly more people to find those who are infected, isolate them and contain the virus.The FDA noted that Abbott’s test could be used in a doctor’s office, emergency room or some schools. “Given the simple nature of this test, it is likely that these tests could be made broadly available,” the FDA said.Since the start of the pandemic, nasal swab tests that are sent to a lab have been the standard for COVID-19 screening. While considered highly accurate, the tests rely on expensive, specialized machines and chemicals. Shortages of those supplies have led to repeated delays in reporting results, especially during a spike in cases last month.Government and health experts view rapid tests that can be run outside the laboratory system as key to boosting capacity.“Those screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” said Dr. Jonathan Quick of the Rockefeller Foundation, in an interview earlier this month. The nonprofit group has called for the U.S. to conduct about 4 millions per day by October, mostly rapid, point-of-care tests.Abbott’s BinaxNOW is the fourth rapid test that detects COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself. It’s considered a faster, though sometimes less precise, screening method. The other tests need to be inserted into a small machine.Inside the Abbott test is a specially coated strip that interacts with COVID-19 antigens. The patient’s nasal swab is inserted into the card and a few drops of a chemical solution are added. Markings appear on the card to indicate whether the sample is positive or negative — much like a pregnancy test.Two other makers of antigen tests — Quidel and Becton Dickinson have said they haven’t been able to meet demand for the tests. A third, LumiraDx, plans to begin shipping its recently approved antigen tests by the end of this month. Abbott expects to begin shipping tests in September, reaching 50 million tests a month in October.The influx of antigen tests will go a long way toward meeting the Trump administration’s projection that 90 million COVID-19 tests a month will be available by September if needed. But U.S. “testing czar” Adm. Brett Giroir has stressed that the U.S. can contain the outbreak with far fewer tests.“That’s the capacity ... we do not need that many tests to safely and sensibly reopen,” Giroir told reporters on a recent call. He pointed to several key indicators that have been falling, including new infections and hospitalizations, even as testing has slowed.Earlier this month, the FDA authorized Yale’s saliva-based test, which is expected to cut the time and cost compared with similar tests. It’s the fifth COVID-19 saliva tests OK’d by regulators. All require lab processing.Developed by Yale’s School of Public Health, SalivaDirect can use any sterile container to collect a sample, not the special tube needed with earlier tests, and requires less chemicals. Outside experts welcomed the new approach but noted its limitations.“It’s not a rapid test, it’s a laboratory-based test that will still be prone to the same massive delays as any other test,” said Dr. Michael Mina of Harvard University.___Follow Matthew Perrone on Twitter: @ AP_FDAwriter.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5201

The CDC reports that the number of flu cases is low right now, and it could be because of safety precautions to slow the spread of the coronavirus, including wearing masks and remaining distant from people in public. Also, high levels of flu vaccinations.The Centers for Disease Control and Prevention tracks flu vaccine distribution and shows, so far for the 2020-2021 season, just under 190 million flu vaccines have been distributed. This compares to about 174 million distributed during the whole 2019-2020 season.According to the CDC’s weekly “flu view” update, “seasonal influenza activity in the United States remains lower than usual for this time of year.”“Overall flu activity is low, and lower than we usually see at this time of year,” Dr. Daniel B. Jernigan, director of the influenza division of the Centers for Disease Control and Prevention, told the New York Times. “I don’t think we can definitively say there will be no twindemic; I’ve been working with flu for a long time, and I’ve been burned. But flu is atypically low.”However, they caution that flu activity may increase in the coming months. Flu season typically peaks at the beginning of the year, depending on the region.The CDC’s map showing state-by-state flu activity shows the majority of the country with “minimal” rates of flu activity, with Oklahoma at a low “moderate” level. A comparison to the 2019-2020 season showed two states were in the moderate level at this time.“The unprecedented demand we’ve seen for flu shots this season, along with safety precautions everyone is taking to limit the spread of COVID-19, such as social distancing, wearing facemasks and frequently washing their hands, may be contributing to lower flu activity this season,” Dr. Kevin Ban, the chief medical officer at Walgreens, said in a written statement.Related: Is it the flu or coronavirus? Walgreens is reporting fewer sales of antiviral medications for flu so far this season compared to 2019. The health and wellness company has a flu tracker each season that tracks regional activity.Health experts remind everyone it is not too late to get the flu vaccine and be protected for the 2020-2021 flu season. 2186

The Detroit Lions have issued a statement in response to reports coach Matt Patricia was indicted on sex assault in a case that was ultimately dismissed.Court records for Cameron County, Texas show Patricia and Gregory Dietrich were indicted in August 1996 on sex assault charges.The case was dismissed in January 1997.The Lions have released the following statements from Matt Patricia and from Lions' owner Martha Firestone Ford, Bob Quinn and Rod Wood.Matt Patricia: 482